McKesson (NYSE:MCK) Reaches New 1-Year High After Earnings Beat

Posted by George Bondi on Nov 6th, 2026

McKesson Corporation (NYSE:MCK – Get Free Report) reached a new 52-week high during trading on Wednesday following a stronger than expected earnings report. The company traded as high as $1,034.11 and last traded at $1,038.0770, with a volume of 236,301 shares. The stock had previously closed at $999.62.

The company reported $11.68 EPS for the quarter, topping the consensus estimate of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. McKesson’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $9.86 EPS.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

More McKesson News

Here are the key news stories impacting McKesson this week:

Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Analyst Ratings Changes

Several brokerages have issued reports on MCK. Robert W. Baird set a $1,015.00 price target on shares of McKesson in a report on Thursday, August 6th. Wall Street Zen raised shares of McKesson from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Bank of America boosted their price objective on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. UBS Group increased their price objective on shares of McKesson from $1,200.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Citigroup raised their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, July 24th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,026.18.

Read Our Latest Research Report on MCK

Insider Activity at McKesson

In other news, Director Bradley E. Lerman sold 301 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Francisco Fraga sold 800 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00. Following the sale, the executive vice president owned 5,423 shares of the company’s stock, valued at approximately $5,400,223.40. This represents a 12.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,462 shares of company stock valued at $2,511,106. Company insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Nvwm LLC grew its holdings in McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new stake in McKesson during the second quarter worth approximately $27,000. Trellis Wealth Advisors LLC bought a new stake in McKesson in the third quarter worth approximately $32,000. Clearstead Trust LLC bought a new position in shares of McKesson during the 2nd quarter worth approximately $37,000. Finally, GK Wealth Management LLC bought a new position in shares of McKesson during the 3rd quarter worth approximately $38,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Trading Down 1.0%

The firm’s 50-day moving average price is $934.72 and its 200 day moving average price is $866.92. The company has a market cap of $123.68 billion, a price-to-earnings ratio of 27.28, a P/E/G ratio of 2.13 and a beta of 0.27.

McKesson Company Profile

(Get Free Report)

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.